Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation

Ibrutinib, a clinically approved irreversible BTK kinase inhibitor for Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL) etc, has been reported to be potent against EGFR mutant kinase and currently being evaluated in clinic for Non Small Cell Lung Cancer (NSCLC). Through EGFR wt/muta...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Main Authors: Wang, Aoli, Yan, Xiao-E, Wu, Hong, Wang, Wenchao, Hu, Chen, Chen, Cheng, Zhao, Zheng, Zhao, Peng, Li, Xixiang, Wang, Li, Wang, Beilei, Ye, Zi, Wang, Jinhua, Wang, Chu, Zhang, Wei, Gray, Nathanael S., Weisberg, Ellen L., Chen, Liang, Liu, Jing, Yun, Cai-Hong, Liu, Qingsong
Formato: Artigo
Idioma:Inglês
Publicado: Impact Journals LLC 2016
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5342513/
https://ncbi.nlm.nih.gov/pubmed/27626175
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.11951
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares